Acute Inflammatory Response of Patients with Pseudomonas aeruginosa Infections: A Prospective Study

Microb Drug Resist. 2017 Jun;23(4):523-530. doi: 10.1089/mdr.2016.0144. Epub 2016 Oct 18.

Abstract

The severity of Pseudomonas aeruginosa (PA) infection may be determined by the interaction with the host immune system. We designed a prospective study to assess the relationship between the inflammatory response and the clinical presentation and outcome of PA infection. We also investigated whether there are differences in the inflammatory response depending on the resistance profile of PA. Interleukin-6 (IL-6), IL-10, procalcitonin (PCT), and C-reactive protein (CRP) were measured. Sixty-nine infection episodes were recorded; 40 caused by non-multidrug-resistant (non-MDR) strains [29 (73%) respiratory; 8 (20%) bacteremia], 12 by MDR non-extensively drug-resistant (MDR-non-XDR) [9 (75%) respiratory; 3 (25%) bacteremia], and 17 by XDR strains [9 (53%) respiratory; 7 (41%) bacteremia]. All inflammatory parameters were significantly higher in patients who developed acute organ dysfunction and bacteremia. PCT levels were higher in patients with early mortality [p = 0.050]. Inflammatory biomarkers were higher in patients with XDR than in those with non-MDR PA [IL-6 430 (67-951) vs. 77 (34-216), p = 0.02; IL-10 3.3 (1.5-16.3) vs. 1.3 (0-3.9), p = 0.02; and PCT 1.1 (0.6-5.2) vs. 0.3 (0.1-1.0), p = 0.008]. The intensity of inflammatory response was associated with the severity of PA infection, particularly if bacteremia occurred. Only PCT was documented useful to predict the outcome. XDR infections presented a higher inflammatory response; related in part to the larger number of bloodstream infections in this group.

Keywords: Pseudomonas aeruginosa; infections; microbial drug resistance; nosocomial infections.

MeSH terms

  • Aged
  • Anti-Bacterial Agents / therapeutic use
  • Bacteremia / drug therapy
  • Bacteremia / immunology*
  • Bacteremia / microbiology
  • Bacteremia / mortality
  • C-Reactive Protein / genetics
  • C-Reactive Protein / immunology
  • Calcitonin / genetics
  • Calcitonin / immunology*
  • Cross Infection / drug therapy
  • Cross Infection / immunology*
  • Cross Infection / microbiology
  • Cross Infection / mortality
  • Drug Resistance, Multiple, Bacterial / physiology
  • Female
  • Gene Expression Regulation
  • Host-Pathogen Interactions
  • Humans
  • Immunity, Innate*
  • Interleukin-10 / genetics
  • Interleukin-10 / immunology
  • Interleukin-6 / genetics
  • Interleukin-6 / immunology
  • Male
  • Middle Aged
  • Prognosis
  • Prospective Studies
  • Pseudomonas Infections / drug therapy
  • Pseudomonas Infections / immunology*
  • Pseudomonas Infections / microbiology
  • Pseudomonas Infections / mortality
  • Pseudomonas aeruginosa / drug effects
  • Pseudomonas aeruginosa / growth & development
  • Pseudomonas aeruginosa / pathogenicity
  • Signal Transduction
  • Survival Analysis
  • Systemic Inflammatory Response Syndrome / drug therapy
  • Systemic Inflammatory Response Syndrome / immunology*
  • Systemic Inflammatory Response Syndrome / microbiology
  • Systemic Inflammatory Response Syndrome / mortality

Substances

  • Anti-Bacterial Agents
  • IL10 protein, human
  • IL6 protein, human
  • Interleukin-6
  • Interleukin-10
  • Calcitonin
  • C-Reactive Protein